These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 22990223)
1. Lack of association of OPRM1 genotype and smoking cessation. Munafò MR; Johnstone EC; Aveyard P; Marteau T Nicotine Tob Res; 2013 Mar; 15(3):739-44. PubMed ID: 22990223 [TBL] [Abstract][Full Text] [Related]
2. Association of the mu-opioid receptor gene with smoking cessation. Munafò MR; Elliot KM; Murphy MF; Walton RT; Johnstone EC Pharmacogenomics J; 2007 Oct; 7(5):353-61. PubMed ID: 17224915 [TBL] [Abstract][Full Text] [Related]
3. Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. Ray R; Jepson C; Wileyto EP; Dahl JP; Patterson F; Rukstalis M; Pinto A; Berrettini W; Lerman C Nicotine Tob Res; 2007 Nov; 9(11):1237-41. PubMed ID: 17978999 [TBL] [Abstract][Full Text] [Related]
4. Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact of communication upon adherence. Marteau TM; Munafò MR; Aveyard P; Hill C; Whitwell S; Willis TA; Crockett RA; Hollands GJ; Johnstone EC; Wright AJ; Prevost AT; Armstrong D; Sutton S; Kinmonth AL BMC Public Health; 2010 Nov; 10():680. PubMed ID: 21062464 [TBL] [Abstract][Full Text] [Related]
5. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Lerman C; Wileyto EP; Patterson F; Rukstalis M; Audrain-McGovern J; Restine S; Shields PG; Kaufmann V; Redden D; Benowitz N; Berrettini WH Pharmacogenomics J; 2004; 4(3):184-92. PubMed ID: 15007373 [TBL] [Abstract][Full Text] [Related]
6. Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trial. Marteau TM; Aveyard P; Munafò MR; Prevost AT; Hollands GJ; Armstrong D; Sutton S; Hill C; Johnstone E; Kinmonth AL PLoS One; 2012; 7(4):e35249. PubMed ID: 22509402 [TBL] [Abstract][Full Text] [Related]
7. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Ray R; Jepson C; Patterson F; Strasser A; Rukstalis M; Perkins K; Lynch KG; O'Malley S; Berrettini WH; Lerman C Psychopharmacology (Berl); 2006 Oct; 188(3):355-63. PubMed ID: 16960700 [TBL] [Abstract][Full Text] [Related]
8. Factors influencing the impact of pharmacogenomic prescribing on adherence to nicotine replacement therapy: A qualitative study of participants from a randomized controlled trial. Wright AJ; Sutton S; Armstrong D; Aveyard P; Kinmonth AL; Marteau TM Transl Behav Med; 2018 Jan; 8(1):18-28. PubMed ID: 29385578 [TBL] [Abstract][Full Text] [Related]
9. Gene-gene interaction of μ-opioid receptor and GluR5 kainate receptor subunit is associated with smoking behavior in a Greek population: presence of a dose allele effect. Misailidis G; Ragia G; Ivanova DD; Tavridou A; Manolopoulos VG Drug Metab Pers Ther; 2015 Jun; 30(2):129-35. PubMed ID: 25941919 [TBL] [Abstract][Full Text] [Related]
10. The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline care (nicotine replacement therapy and behavioural support), on smoking cessation: a randomized controlled trial. Walker N; Howe C; Bullen C; Grigg M; Glover M; McRobbie H; Laugesen M; Parag V; Whittaker R Addiction; 2012 Oct; 107(10):1857-67. PubMed ID: 22594651 [TBL] [Abstract][Full Text] [Related]
11. A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation. Verhagen M; Kleinjan M; Engels RC Pharmacogenomics; 2012 Jun; 13(8):917-33. PubMed ID: 22676196 [TBL] [Abstract][Full Text] [Related]
12. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation. Becker KM; Rose JE; Albino AP Nicotine Tob Res; 2008 Jul; 10(7):1139-48. PubMed ID: 18629723 [TBL] [Abstract][Full Text] [Related]
13. Varying nicotine patch dose and type of smoking cessation counseling. Jorenby DE; Smith SS; Fiore MC; Hurt RD; Offord KP; Croghan IT; Hays JT; Lewis SF; Baker TB JAMA; 1995 Nov; 274(17):1347-52. PubMed ID: 7563558 [TBL] [Abstract][Full Text] [Related]
14. Nicotine withdrawal sensitivity, linkage to chr6q26, and association of OPRM1 SNPs in the SMOking in FAMilies (SMOFAM) sample. Hardin J; He Y; Javitz HS; Wessel J; Krasnow RE; Tildesley E; Hops H; Swan GE; Bergen AW Cancer Epidemiol Biomarkers Prev; 2009 Dec; 18(12):3399-406. PubMed ID: 19959688 [TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of nicotine replacement therapy for smoking cessation in adolescents: a randomized controlled trial. Scherphof CS; van den Eijnden RJ; Engels RC; Vollebergh WA Drug Alcohol Depend; 2014 Jul; 140():217-20. PubMed ID: 24811201 [TBL] [Abstract][Full Text] [Related]
16. Family support and employment as predictors of smoking cessation success: a randomized, double-blind, placebo-controlled trial of nicotine sublingual tablets in chinese smokers. Sun HQ; Guo S; Chen DF; Jiang ZN; Liu Y; Di XL; Yang FD; Zhang XY; Kosten TR; Lu L Am J Drug Alcohol Abuse; 2009; 35(3):183-8. PubMed ID: 19462302 [TBL] [Abstract][Full Text] [Related]
17. Improving the effectiveness of smoking cessation in primary care: lessons learned. Richards D; Toop L; Brockway K; Graham S; McSweeney B; MacLean D; Sutherland M; Parsons A N Z Med J; 2003 May; 116(1173):U417. PubMed ID: 12740611 [TBL] [Abstract][Full Text] [Related]
18. [Smoking reduction and temporary abstinence: new approaches for smoking cessation]. Le Houezec J; Säwe U J Mal Vasc; 2003 Dec; 28(5):293-300. PubMed ID: 14978435 [TBL] [Abstract][Full Text] [Related]